Please use this identifier to cite or link to this item:
Calcium channel blocker amlodipine besylate is associated with reduced case fatality rate of COVID-19 patients with hypertension
Leike Zhang.
Yuan Sun.
Hao-Long Zeng.
Yudong Peng.
Xiaming Jiang.
Wei-Juan Shang.
Yan Wu.
Shufen Li.
Yu-Lan Zhang.
Liu Yang.
Hongbo Chen.
Runming Jin.
Wei Liu.
Hao Li.
Ke Peng.
Gengfu Xiao.
Acceso Abierto
The coronavirus disease (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread to more than 100 countries posing as a serious threat to the public health on a global scale. Patients with comorbidity such as hypertension suffer more severe infection with elevated case fatality rate. Development of effective anti-viral drug is in urgent need to treat COVID-19 patients. Here we report that calcium channel blockers (CCBs), a type of anti-hypertension drugs that are widely used in the clinics, can significantly inhibit the post-entry replication events of SARS-CoV-2 in vitro. Comparison with two other major types of anti-hypertension drugs, the angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), showed that only CCBs display significant anti-SARS-CoV-2 efficacy. Combined treatment with chloroquine and CCBs significantly enhanced the anti-SARS-CoV-2 efficacy. Retrospective clinical investigation of COVID-19 patients revealed that the CCB amlodipine besylate administration distinctly reduced the case fatality rate of patients with hypertension. Results from this study suggest that CCB administration for COVID-19 patients with hypertension as the comorbidity might improve the disease outcome.
Appears in Collections:Artículos científicos

Upload archives

File SizeFormat 
1104079.pdf1.06 MBAdobe PDFView/Open